BFRI
NASDAQBiofrontera Inc.
Price$0.97+0.06 (+6.38%)
2026-03-022026-06-03
News · 26 weeks35+200%
2025-12-072026-05-31
Mix2190d
- Insider7(33%)
- SEC Filings6(29%)
- Earnings4(19%)
- Other3(14%)
- Analyst1(5%)
Latest news
25 items- PRBiofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026. Company Webcast The webcast presentation will take place at 11:00 a.m. ET on Thursday, May 28, 2026. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2026/ or directly at https://app.webinar.net/xrp2JnwZa5Y. The webcast will
- ANALYSTBiofrontera Inc. downgraded by The Benchmark Company with a new price targetThe Benchmark Company downgraded Biofrontera Inc. from Buy to Speculative Buy and set a new price target of $3.00
- SECSEC Form 10-Q filed by Biofrontera Inc.10-Q - Biofrontera Inc. (0001858685) (Filer)
- SECBiofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Biofrontera Inc. (0001858685) (Filer)
- PRBiofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business UpdateWoburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 and provided a business update. First Quarter Financial Highlights Revenues for Q1 2026 were $10.1 million, a ~17% increase compared to $8.6 million for the same period in 2025.Gross margins were about 80%, an 18 percentage points increase compared to approximately 62% in Q1 2025, reflecting the first full quarter under the new earnout structure following the closing of the strategic transaction w
- PRBiofrontera Launches Second Annual "Hats On" Campaign to Raise Awareness of Actinic KeratosisThe second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness DayThis social media–driven initiative invites people to wear a hat, share a photo, and help raise awareness of AK and the importance of comprehensive sun protectionActinic Keratosis affects an estimated 58 million Americans and, if left untreated, can develop into squamous cell carcinoma1 Woburn, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the return of the Hats On Campaign for its seco
- PRBiofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Thursday, May 14, 2026. The Company will host a conference call on Thursday, May 14, 2026 at 11:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.Conference Call and Webcast Information Event:Biofrontera Inc. First Quarter 2026 Financial Results and Business Update Conference CallDate:Thursday
- SECSEC Form DEF 14A filed by Biofrontera Inc.DEF 14A - Biofrontera Inc. (0001858685) (Filer)
- SECSEC Form 10-K filed by Biofrontera Inc.10-K - Biofrontera Inc. (0001858685) (Filer)
- SECBiofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Biofrontera Inc. (0001858685) (Filer)
- PRBiofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateConference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transitio
- PRBiofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information Event:Biofrontera Inc. Fourth Quarter and Full Year 2025 Financial Results and Busi
- SECBiofrontera Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Biofrontera Inc. (0001858685) (Filer)
- PRBiofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz® PDT versus vehicle • 3-hour incubation regimen identified as the most promising protocol for further clinical development • Acne vulgaris represents a promising potential future indication for Ameluz®, significantly broadening the Company's dermatology pipeline WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced results of its Phase 2b clinical trial evaluating Ameluz® (aminolevulinic acid HCL) topical gel, 1
- INSIDERSEC Form 4 filed by Director Weber Kevin Daniel4 - Biofrontera Inc. (0001858685) (Issuer)
- INSIDERCEO & Chairman Luebbert Hermann converted options into 137,500 shares, increasing direct ownership by 90% to 290,211 units (SEC Form 4)4 - Biofrontera Inc. (0001858685) (Issuer)
- INSIDERChief Financial Officer Leffler Eugene Frederick converted options into 87,500 shares, increasing direct ownership by 100% to 175,000 units (SEC Form 4)4 - Biofrontera Inc. (0001858685) (Issuer)
- INSIDERSEC Form 4 filed by Director Lanckriet Heikki4 - Biofrontera Inc. (0001858685) (Issuer)
- INSIDERSEC Form 4 filed by Director Hoffman Beth J.4 - Biofrontera Inc. (0001858685) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Jones George Patrick4 - Biofrontera Inc. (0001858685) (Issuer)
- INSIDERSEC Form 4 filed by Director Borer John J Iii4 - Biofrontera Inc. (0001858685) (Issuer)
- SECBiofrontera Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Biofrontera Inc. (0001858685) (Filer)
- PRU.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be UnpatentableWOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT"), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the "Board") issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.'s U.S. Patent No. 11,697,028 (the "'028 Patent") to be unpatentable. As previously disclosed in Biofrontera's filings with the Securities and Exchange Commission, in June 2024, Sun Pharma initiated proceedings against Biofrontera and certain of its affiliates in the U.S. District Court for the District
- PRBiofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and ExtremitiesPhase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansionData to complement previously announced positive Phase 3 efficacy results on extremities, neck and trunkSupplemental NDA submission for extremities, neck and trunk indication expected in Q3 2026 WOBURN, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced that the database of its Phase 1 PK study evaluating Ameluz® (aminolevulinic acid hydrochloride) topical gel for the treatment of mild to moderate actinic kera
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.SCHEDULE 13G/A - Biofrontera Inc. (0001858685) (Subject)
BFRI FAQ
7 questionsWhat does Biofrontera Inc. do?
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.Where does BFRI stock trade?
Biofrontera Inc. (BFRI) is listed on NASDAQ.What sector and industry is BFRI in?
Biofrontera Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Biofrontera Inc. go public?
Biofrontera Inc. (BFRI) completed its IPO in 2021.What are analysts saying about BFRI?
Biofrontera Inc. has had 3 recent analyst actions on file. The most recent action was from The Benchmark Company: Speculative Buy with a $300.00 price target on 2026-05-19.What companies are similar to BFRI?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BFRI side-by-side with any of them on Quantisnow.How can I track BFRI on Quantisnow?
Quantisnow aggregates Biofrontera Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BFRI to receive live email and push alerts on every new disclosure.